# Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

> **NCT05505175** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05505175
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-30
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-05-02
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05505175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05505175, "Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05505175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*